Faculty profile

Sean Wharton

Back to faculty

Assistant Clinical Professor (Adjunct)MedicineMcMaster University

Sean Wharton

Assistant Clinical Professor (Adjunct)

Medicine

Faculty of Health Sciences

McMaster University

Hamilton, Ontario, Canada

In this role since 2016

Email ORCID

Supervision signals

Adjunct, part-time and visiting faculty usually co-supervise alongside a core faculty member.
No graduate courses on record.
120 publications in the last five years, latest in 2026.
Senior (last) author on 14 recent papers, a sign of leading a research group.
Principal investigator on 1 CIHR grant, most recently in 2017.

These signals come from public records. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

202

Publications

19,266

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Academic profiles

University Profile Search on Google Scholar iDORCID OpenAlex

Social profiles

𝕏Search on X inSearch on LinkedIn 🦋Search on Bluesky ▶Search on YouTube

Contact

whartosn@mcmaster.ca (905) 527-4322 ext. 42446

Research

Research areas, by share of publications

Diabetes Treatment and ManagementMedicine
Bariatric Surgery and OutcomesMedicine
Pharmacology and Obesity TreatmentMedicine
Obesity and Health PracticesHealth Professions
Metabolism, Diabetes, and CancerBiochemistry, Genetics and Molecular Biology

Research areas are derived from OpenAlex topics of their publications.

From the 150 most recent of 202 publications.

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Hjelmesæth J, Bhat S, Garvey WT, Kolnes KJ, Linge J, Lingvay I, Rasmussen NK, Rosenstock J, Wharton S

Diabetes, Obesity and Metabolism2026Senior author

DOI: 10.1111/dom.71323

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

Horn DB, Aronne LJ, Wharton S, Bays HE, le Roux CW, Srinath R, Gomez-Valderas E, Arad AD, Das S, Dunn JP

The Lancet202625 citations

DOI: 10.1016/s0140-6736(26)00656-2

Survodutide Once Weekly for the Treatment of Adults with Obesity

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P

New England Journal of Medicine202613 citations

DOI: 10.1056/nejmoa2600751

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW

Nature Medicine202611 citations

DOI: 10.1038/s41591-026-04479-3

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Hussain SA, Brueckmann M, Startseva E, Kloer IM, Kaplan LM

Diabetes, Obesity and Metabolism20268 citations

DOI: 10.1111/dom.70196

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Hussain SA, Brueckmann M, Startseva E, Kloer IM, Kaplan LM

Diabetes, Obesity and Metabolism20265 citationsFirst author

DOI: 10.1111/dom.70263

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Overgaard RV, Birkhan O, Rathor N, Sparsø T, Strathe A, Wharton S, Rubino D

Diabetes, Obesity and Metabolism20265 citations

DOI: 10.1111/dom.70769

Management of brain–heart multimorbidity: a clinical practice guideline

Edwards JD, Li Z, McFarlane P, Rabi DM, Gilbert J, Bajaj HS, MacIntosh BJ, Bittman J, Feldman RD, Dresser G

CANADIAN MEDICAL ASSOCIATION JOURNAL20265 citations

DOI: 10.1503/cmaj.251137

CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

Schnell O, Agarwal A, Azizi M, Ballwieser D, Barnard-Kelly K, Battelino T, Ballwieser D, Blüher M, Bugianesi E, Cebrian A

Cardiovascular Diabetology20263 citations

DOI: 10.1186/s12933-026-03140-0

Survodutide for the Treatment of Obesity Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial

Platz E, Kaplan LM, le Roux CW, Wharton S, Burger S, Hussain SA, Brueckmann M, Startseva E, Fey C, Kosiborod MN

JACC: Heart Failure20262 citations

DOI: 10.1016/j.jchf.2025.102780

Researchers with similar interests

Hertzel Gerstein

Medicine

Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer

Natalia McInnes

Medicine

Diabetes Treatment and Management

Manoela Braga

Medicine

Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer

Zubin Punthakee

Medicine

Diabetes Treatment and Management

Ari Doumouras

Surgery

Bariatric Surgery and Outcomes

Dennis Hong

Surgery

Bariatric Surgery and Outcomes

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student: Diabetes Treatment and Management Dear Professor Wharton, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Open in email

Something wrong or missing on this profile? Suggest a correction

Sean Wharton

Research

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

Survodutide Once Weekly for the Treatment of Adults with Obesity

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Management of brain–heart multimorbidity: a clinical practice guideline

CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

Survodutide for the Treatment of Obesity Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial

Frequent collaborators

Diana Sherifali

Valerie Taylor

Richard Tytus

Megha Poddar

Dennis Hong

Tracy Vaillancourt

Researchers with similar interests

Hertzel Gerstein

Natalia McInnes

Manoela Braga

Zubin Punthakee

Ari Doumouras

Dennis Hong